Healthcare / Diagnostics & ResearchJakartaID
$226.00
+18.00 (+8.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.1B · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$310.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
1.4%
↑Gross Margin
43.0%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+36.3%
FCF CAGR
—
FCF margin
1.6%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $166.62B · net income $2.94B · FCF $2.58B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $166.62B | $166.62B | $163.07B | $145.70B | $192.89B | $302.18B | $183.17B | $51.34B | $38.55B | $14.01B |
| Net Income | $2.94B | $2.94B | $747.4M | $-13.66B | $12.66B | $64.30B | $52.69B | $9.27B | $9.26B | $1.38B |
| EBITDA | $16.40B | $16.40B | $16.63B | $1.53B | $31.39B | $90.84B | $70.82B | $14.90B | $12.64B | $1.85B |
| EPS | 2.35 | 2.35 | 0.60 | -10.92 | 10.13 | 51.44 | 42.15 | 7.42 | 7.41 | 1.11 |
| Gross Margin | 43.0% | 43.0% | 39.5% | 40.7% | 45.8% | 48.9% | 46.9% | 38.0% | 42.9% | 33.6% |
| Operating Margin | 3.1% | 3.1% | 1.4% | -9.6% | 9.2% | 26.9% | 36.6% | 25.7% | 32.3% | 13.8% |
| Net Margin | 1.8% | 1.8% | 0.5% | -9.4% | 6.6% | 21.3% | 28.8% | 18.1% | 24.0% | 9.9% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.39 | 0.39 | 0.37 | 0.29 | 0.10 | 0.07 | 0.03 | 0.08 | 0.39 | 0.04 |
| Current Ratio | 3.30 | 3.30 | 3.64 | 6.08 | 11.28 | 5.78 | 3.44 | 1.25 | 1.03 | 2.23 |
| Cash Flow | ||||||||||
| Free Cash Flow | $2.58B | $2.58B | $-16.10B | $-25.14B | $-40.87B | $-8.97B | $20.36B | $8.41B | $4.63B | $-1.04B |
| Returns | ||||||||||
| ROE | 1.4% | 1.4% | 0.4% | -7.0% | 6.0% | 31.9% | 53.2% | 20.0% | 69.8% | 42.9% |
| Growth & Yield | ||||||||||
| Revenue Growth | 2.2% | 2.2% | 11.9% | -24.5% | -36.2% | 65.0% | 256.8% | 33.2% | 175.1% | — |
| EPS Growth | 293.0% | 293.0% | 105.5% | -207.8% | -80.3% | 22.0% | 468.1% | 0.1% | 570.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
104.4%
EPS terminal req.
$20.05
Spread vs growth
188.6%
5Y implied EPS CAGR
59.5%
EPS terminal req.
$24.27
Spread vs growth
233.4%
10Y implied EPS CAGR
32.5%
EPS terminal req.
$39.08
Spread vs growth
260.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+39.5%
Start / end P/E
270.9x → 96.2x
EPS bridge
0.60 → 2.35
Residual
-188.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.